New evidence of efficacy of transcorneal electrical stimulation (TES)

27. February 2023

New evidence of efficacy of transcorneal electrical stimulation (TES)

New analysis shows that OkuStim® therapy can significantly slow progression in patients with retinitis pigmentosa (RP).

The recent analysis of an earlier clinical study has established final proof for the efficacy of the OkuStim therapy. The data show that this therapeutic approach – developed in Germany – significantly slows down visual field progression in RP.

A number of therapies have been tried in retinitis pigmentosa in the past. Currently, the focus of research is on gene therapy and stem cell therapy, although these options are not yet ripe for clinical routine management. Gene therapy in particular typically requires an invasive intervention with a high potential for adverse events.
By contrast, the non-invasive electrical stimulation therapy (OkuStim®), developed by Okuvision, a medical device company based in Reutlingen, Germany, has been used in 52 patients vs. placebo in the study. During TES, an electrode is placed on the lower lid and has contact with the eyeball at the inferior corneal limbus. Treatment with electrical impulses of max. 1 mA and 20 Hz takes 30 minutes, is performed once a week and can be applied by the patients themselves at home after a short instruction and training by their physician.

Of the patients (average age: 46 years) enrolled in the study, 32 individuals received weekly electrical stimulation between 0.1 and 1.0 mA on one eye; 20 patients received sham treatment (placebo group). Following a year of treatment, the eyes that had undergone TES displayed a visual field loss of 2.1% while their untreated contralateral eyes had an average visual field progression of 5.8%. In the placebo group, however, the annual decline was 7.5%. Thus, the decrease in visual field area measured by kinetic perimetry was a remarkable 64% less in the eyes treated with TES than in the untreated eyes (p=0.013) and 72% less than in the placebo group (p=0.103). Slowing the progression was dose-dependent on the extent of the stimulation. In 23 of the treated eyes, dry eye symptoms were noticed as the most frequent ocular adverse event.

Decelerating this progression, this is the study authors’ conclusion, offers the chance to significantly delay severe visual loss and disability. The exact mechanism of action of TES has not yet been fully understood. Experts suggest a neuroprotective effect independent of the genetic cause of RP – an effect that should be put to use in patients as early as possible and at a disease stage before visual function is compromised.

Here you can download the full press release on the current publication.

Click here to go directly to the publication.

Retina UK Konferenz 2021

27. March 2021

Retina UK Conferences 2021

OkuStim therapy featured in this year's Retina UK conference programme.

Retina UK’s Professionals’ and Annual Conferences will be held online in April and registration is now open.

We will introduce the OkuStim therapy as part of the ‘Update from Industry’ session in the programme of the Annual Conference on 17. April.
The OkuStim therapy is available in the UK now.

Professionals’ Conference
Friday 16 April 10.00am – 1.30pm

The Professionals’ Conference builds upon the success of the inaugural event in 2019, and will be held on Friday 16 April. It will start at 10.00am and finish at 1.30pm.

This Conference is aimed at professionals working with people affected by Inherited Retinal Dystrophies and their families.

There are two key themes to this year’s event, Genetics and Mental Health. Speakers include:

  • Dr Panagiotis Sergouniotis who will speak about the clinical importance of genetic testing and research
  • Dr Ian McCubbin, a Clinical Psychologist, who will discuss helping your clients with mental health challengess
  • Professor James Bainbridge, who will be joined by one of the first patients to receive the Luxturna treatment
  • The Retina UK team, who will be launching our new and exciting Unlock Genetics website.

There will be the opportunity to ask questions throughout the day. Registration is open for this free to attend conference. Please complete the online form at

Annual Conference and AGM
Saturday 17 April 10.00am – 2.45pm

All are welcome to join this online event. There will be an exciting line-up of speakers including:

  • Professor Alison Hardcastle, who will be giving us a run-down of the latest genetics research and information about genetic counselling and what it means for you
  • Dr Sam Da Silva, who will tell us about the latest in clinical research
  • The Retina UK team, who will be launching our new Unlock Genetics website.
  • Representatives from the pharmaceutical and medical device industry who will give presentations on some of their cutting edge work to find treatments.

There will be the opportunity to ask questions through the day. Registration is now open, please visit and complete the form, or call the Retina UK team on +44 (0) 1280 821334.

RP, a rare disease

26. February 2021

RP, a rare disease

There are 300 million people worldwide living with a rare disease. In Germany alone there are around 4 million. Most of the more than 6,000 different rare diseases are of genetic origin. Retinitis pigmentosa (RP) is one of them.
About one in 4,000 people is affected. There are therapies for only about 3% of rare diseases – the OkuStim therapy for RP is one of them. It can preserve your vision.

We are continuously working to make the OkuStim therapy more accessible. We are expanding our network – now also in Great Britain. Your feedback on the OkuStim therapy is our motivation to continue working for the treatment of rare diseases.

Best wishes,

New Competence Centre London

17. February 2021

New Competence Centre London

OkuStim Therapy now also in UK

The OkuStim therapy for retinitis pigmentosa is now also available for you in Great Britain.

Your contact at the Harley Street Eye Centre is Dr. Hakam Ghabra.

Harley Street Eye Centre

22A Harley Street
London W1G 9BP, UK

Dr. Hakam Ghabra

Tel.: +44 (0) 20 3968 2030
Mob.: +44 (0) 750 232 0504

Transcorneal electrical stimulation (TES) with OkuStim is the only available topically applied treatment for retinitis pigmentosa with clinically proven safety and efficacy. OkuStim therapy can slow the disease and progressive loss of visual field.